Recent developments include a reported earnings drop in August 2025 and an increase in a major investor's position in early 2023.

• Interpace Biosciences reported an earnings drop in August 2025 [N1].
• Investor Singer Douglas Mark increased his position in Interpace Diagnostics Group in February 2023 [N2].

The company’s positive net income and earnings per share in 2025, combined with a current ratio near 2, indicate operational profitability and liquidity. Experienced leadership and active investor interest, as evidenced by recent position increases, support business continuity and potential strategic initiatives. The equity incentive plans may foster management alignment with shareholder interests.

Recent news reports an earnings drop in August 2025, which may indicate volatility or challenges in revenue generation. The company’s revenue figure is from 2022, with no more recent revenue disclosed, which may suggest limited growth visibility. The absence of detailed disclosure on market segments or competitive advantages limits clarity on long-term sustainability. Risk factors disclosed in SEC filings highlight potential material impacts on business and financial condition.

Interpace Biosciences benefits from experienced leadership with extensive backgrounds in clinical diagnostics and life sciences, as well as established equity incentive programs to align management and board interests with shareholders. The company’s liquidity position and positive net income in recent fiscal years support operational stability. However, detailed information on proprietary technology, competitive positioning, or barriers to entry is not explicitly disclosed in the available filings.

• Business and Financial Risks: The company’s SEC filings disclose risk factors that could materially harm its business, operating results, and financial condition. These include uncertainties not currently known or considered immaterial that may adversely affect future results [S2].
• Earnings Volatility: Recent news reports an earnings drop in August 2025, indicating potential volatility in financial performance [N1].
• Limited Recent Revenue Disclosure: The latest disclosed revenue figure is for fiscal year 2022, limiting visibility into recent revenue trends [S1].

• Interpace Biosciences, Inc. is a publicly reporting company with SEC filings including a 10-K/A filed on 2026-04-30 covering fiscal year ended December 31, 2025 [S1].
• The company is incorporated in Delaware and headquartered in Parsippany, NJ.
• As of April 15, 2026, the company had 27,700,904 shares of common stock issued and outstanding [S1].
• The Board of Directors consists of five members divided into three classes with staggered three-year terms [S1].
• Key executives include Thomas W. Burnell as President, CEO, and Chairman of the Board, and Christopher McCarthy as CFO and COO [S1].
• The company had cash and cash equivalents of $2.505 million and current assets of $9.9 million as of December 31, 2025 [S1].
• Current liabilities were $5.103 million as of December 31, 2025, resulting in a current ratio of 1.94 and a cash ratio of 0.76 [S1].
• Revenue reported for the fiscal year ended December 31, 2022 was $5.678 million [S1].
• Net income for the fiscal year ended December 31, 2025 was $24.575 million [S1].
• Basic earnings per share for 2025 were $5.55 and diluted EPS was $0.89 [S1].
• The company has a 2019 Equity Incentive Plan under which executives and directors receive stock options and restricted stock units [S1].
• The CEO's 2025 base salary was $460,625 with a target annual bonus of up to 50% of base salary [S1].
• The CFO's 2025 base salary was $325,000 with a target annual bonus of up to 40% of base salary [S1].
• Non-employee directors receive annual fees and stock option grants; the 2025 annual director fee was $40,000 plus $10,000 for committee chairs [S1].
• The company has publicly disclosed risk factors in its 10-K filings that could materially affect its business and financial condition [S2].
• Recent news includes a report of earnings drop in August 2025 [N1].
• An investor, Singer Douglas Mark, increased his position in the company in February 2023 [N2].